Outpatient Surgery Magazine

OR Excellence Awards - September 2020 - Subscribe to Outpatient Surgery Magazine

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://magazine.outpatientsurgery.net/i/1284191

Contents of this Issue

Navigation

Page 64 of 71

L ast month, the FDA issued an alert about potential risks associated with the intraocular use of compounded moxifloxacin. The FDA had received reports of toxic anterior segment syn- drome (TASS) following injections of compounded drugs containing bulk moxifloxacin or repackaged and diluted FDA-approved moxifloxacin medica- tions. A search of the FDA's Adverse Event Reporting System database identified 29 cases of TASS associated with drugs containing moxifloxacin. Among the reports, 16 involved drugs compounded with bulk moxifloxacin; 10 were associated with repackaged Moxeza, a preservative-containing form of moxifloxacin; the remaining incidents involved unspecified (repackaged and/or diluted) forms of Vigamox and Moxeza. Nineteen cases involved cataract surgery; the others did not specify the type of eye surgery in which the drugs were used. The FDA released the alert to inform providers that it's considering placing bulk moxifloxacin on the list of medications that should not be com- pounded for ophthalmic use. Many ophthalmic sur- geons administer moxifloxacin during cataract sur- gery to reduce the risk of post-op endophthalmitis, which the FDA says is estimated to occur in .012% to 1.3% of cases. There is no FDA-approved moxifloxacin product, but approximately half of ophthalmic surgeons administer intracameral moxifloxacin at the time of cataract surgery, according to Eric Donnenfeld, MD, a cataract specialist at Ophthalmic Consultants of Long Island in Garden City, N.Y. "Approximately four million cataract cases are performed each year, so about 2 million patients are administered intra- cameral moxifloxacin annually," he says. "With that perspective, twenty-nine cases of TASS is a very low number." S E P T E M B E R 2 0 2 0 • O U T P A T I E N T S U R G E R Y . N E T • 6 5 Dan Cook | Editor-in-Chief FDA Issues Caution Over Moxifloxacin Eye Injections Compounded forms of the drug have been associated with toxic anterior segment syndrome. PREVENTATIVE MEASURE Many surgeons inject moxifloxacin at the time of cataract surgery to reduce the risk of post-op endophthalmitis. Pamela Bevelhymer, RN, BSN, CNOR

Articles in this issue

Archives of this issue

view archives of Outpatient Surgery Magazine - OR Excellence Awards - September 2020 - Subscribe to Outpatient Surgery Magazine